Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 11/20 | 0.60 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2321683 | 0.83 | ROCK2 (0.59) | ROCK2ROCK1HRH4SMN1; SMN2 | |
| SCHEMBL2324318 | 0.81 | ROCK2 (0.58) | ROCK2ROCK1HRH4 | |
| SCHEMBL2318777 | 0.81 | ROCK2 (0.62) | ROCK2ROCK1HRH4CYP1A2CYP3A4 | |
| SCHEMBL2320533 | 0.80 | ROCK2 (0.61) | ROCK2ROCK1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12440600 | 0.75 | ROCK2 (1.00) | ROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL2326313 | 0.74 | ROCK2 (0.98) | ROCK2ROCK1 | |
| SCHEMBL13226149 | 0.68 | ROCK2 (0.60) | ROCK2ROCK1 | |
| SCHEMBL2322251 | 0.68 | ROCK2 (0.60) | ROCK2ROCK1HRH4 | |
| SCHEMBL2319190 | 0.68 | ROCK2 (0.65) | ROCK2ROCK1HRH4 | |
| SCHEMBL2320475 | 0.65 | ROCK2 (0.68) | ROCK2ROCK1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1830853-B1 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2011-08-10 | — | — | EP | disclosed |
| US-20100216777-A1 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON, INC. (CH) | 2010-08-26 | — | — | US | disclosed |
| US-20080269249-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON, INC. (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20060142307-A1 | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | ALCON, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216777-A1 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885HRH4 631/4885 |
| US-20080269249-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885HRH4 631/4885 |
| US-20060142307-A1 | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885HRH4 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.